Clinical trialNCT07212868RecruitingPhase 1Interventional

The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

SponsorThe University of Texas Health Science Center at San AntonioEnrollment150Non-Diabetic

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is involved with measuring glucose metabolism with glucagon infusion and glucagon receptor blockade. We use an investigational drug called REMD 477. "Investigational" means that the has not yet been approved by the U.S. Food \& Drug Administration (FDA). REMD-477 is a monoclonal antibody (an antibody made by cloning a unique white blood cell) that blocks the effect of glucagon.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Marzieh Salehi, MD, MS
The University of Texas Health Science Center at San Antonio
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Texas Diabetes Institute - University Health System
San Antonio, Texas, United States
Marzieh Salehi, MD MS
Recruiting
University of Texas San Antonio
San Antonio, Texas, United States
Marzieh Salehi, MD, MS
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

REMD-477 versus Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Feb 2026
Primary completion: 1 May 2030
Completion: 30 Jun 2030
Last update posted: 11 May 2026
Registered enrollment: 150
Registry id: NCT07212868

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.